Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Thermo Fisher Scientific Inc. Revenue & Financial Statements
Thermo Fisher Scientific Inc. reported revenue of $44.6B for the fiscal year ended December 31, 2025, up 3.9% year over year, with net income of $6.7B and diluted EPS of $17.74.
- Company
- Thermo Fisher Scientific Inc. TMO · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 39.2B | 44.9B | 42.9B | 42.9B | 44.6B |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | 10.0B | 8.4B | 6.9B | 7.3B | 7.7B |
| Pretax income | 3.3B | 3.9B | 2.4B | 2.2B | 4.7B |
| Net income | 7.7B | 7.0B | 6.0B | 6.3B | 6.7B |
| Diluted EPS | 19.46 | 17.63 | 15.45 | 16.53 | 17.74 |
| EBITDA | 10.9B | 9.4B | 7.9B | 8.5B | 8.8B |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.3B | 10.5B | 10.6B | 11.4B | 10.4B | 10.9B | 11.1B | 12.2B |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | 1.7B | 1.8B | 1.8B | 2.0B | 1.7B | 1.8B | 1.9B | 2.3B |
| Pretax income | — | — | — | — | — | — | — | — |
| Net income | 1.3B | 1.5B | 1.6B | 1.8B | 1.5B | 1.6B | 1.6B | 2.0B |
| Diluted EPS | 3.46 | 4.04 | 4.25 | 4.78 | 3.98 | 4.28 | 4.27 | 5.21 |
| EBITDA | 1.9B | — | 2.1B | 2.3B | 2.0B | 2.1B | 2.2B | 2.5B |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2024 | FY2024 | FY2025 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Total assets | — | 97.3B | — | 110.3B | — |
| Current assets | — | 22.1B | — | 28.7B | — |
| Cash & equivalents | — | 4.0B | — | 9.9B | — |
| Total liabilities | — | — | — | — | — |
| Current liabilities | — | 13.3B | — | 15.2B | — |
| Long-term debt | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Stockholders’ equity | — | 49.6B | — | 53.4B | — |
| Net debt | — | — | — | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 9.3B | 9.2B | 8.4B | 8.7B | 7.8B |
| Investing cash flow | (21.9B) | (2.2B) | (5.1B) | (5.8B) | (4.0B) |
| Financing cash flow | 6.6B | (2.8B) | (3.6B) | (6.8B) | 1.8B |
| Capital expenditure | 2.5B | 2.2B | 1.5B | 1.4B | 1.5B |
| Free cash flow | 6.8B | 6.9B | 6.9B | 7.3B | 6.3B |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 230.0M | 307.0M | 278.0M | 301.0M | 310.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every TMO filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.